Breaking Finance News

A statement released earlier today by Citigroup about Becton Dickinson and Co. (NYSE:BDX) bumps down the target price to $165.00

Boasting a price of $181.55, Becton Dickinson and Co. (NYSE:BDX) traded -1.32% lower on the day. With the last close up 7.52% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $175.12 and a 200-day moving average of $166.62. 115,749 shares of BDX traded hands, down from an average trading volume of 820,575

Citigroup bumped down the target of Becton Dickinson and Co. (NYSE:BDX) to $165.00 stating a potential downside of -0.09%.

On 8/05/2016, UBS Securities released a statement for Becton Dickinson and Co. (NYSE:BDX) bumped up the target price from $182.00 to $195.00 that suggested an upside of 0.12%.

Recent Performance Chart

Becton Dickinson and Co. (NYSE:BDX)

Becton Dickinson and Co. has 52 week low of $128.87 and a 52 week high of $181.76 with a P/E ratio of 34.19 and has a market cap of $0.

In addition to Citigroup reporting its stock price target, a total of 16 brokers have issued a research note on the company. The average stock price target is $173.94 with 6 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 7 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Becton Dickinson and Co. (NYSE:BDX)

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates through two business segments: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. The Company's products include hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; BD Vacutainer brand blood collection products, and flow cytometry instruments and reagents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.